DIA Biosimilars 2013

Ambit Biosciences

Astellas, Ambit terminate collaboration on FLT3 kinase inhibitors

Wednesday, March 13, 2013 10:39 AM

Tokyo-based Astellas Pharma and San Diego-based Ambit Biosciences will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013.

More... »

Cenduit: Now with Patient Reminders

Ambit Biosciences registers for proposed IPO

Friday, February 22, 2013 10:47 AM

Ambit Biosciences, a privately held biopharmaceutical company, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for an initial public offering of its common stock on the NASDAQ stock market.

More... »

CRF Health – eCOA Forum

Ambit completes $25M financing for AML drug

Wednesday, November 7, 2012 10:36 AM

Ambit Biosciences, a privately held biopharmaceutical company based in San Diego, has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib, for the treatment of acute myeloid leukemia (AML).

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.